Sawai Will Focus On New SA1 And Cilostazol To Match Japan Welfare Policies Etc.
This article was originally published in PharmAsia News
Executive Summary
Sawai is focusing its efforts on newly launched cancer drug SA1 listed in June and anti-platelet drug cilostazol, originally known as Pletal, President Mitsuo Sawai told a press conference in Tokyo.